The Spectrum of α-Thalassemia Mutations in the Lak Population of Iran. 2019

Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
a Medical Biology Research Center , Kermanshah University of Medical Sciences , Kermanshah , Iran.

α-Thalassemia (α-thal) is one of the most common genetic disorders worldwide. The aim of this study was to investigate for the first time the α-thal mutation spectrum in the Lak population living in Lorestan Province, Iran. One hundred and seventy-six α-thal carriers participated in the study. Multiplex gap-polymerase chain reaction (gap-PCR), amplification refractory mutation system (ARMS)-PCR and direct sequencing were used for the detection of different mutations on the α-globin (HBA1 and HBA2) genes. A total of 11 different mutations was identified. The -α3.7 (rightward; NG_000006.1: g.34164_37967del3804) deletion was observed most frequently (56.35%), followed by α-5 ntα (HBA2: c.95+2_95+6delTGAGG), αpolyA2α (HBA2: c.*92A>G) and - -MED I (NG_000006.1: g.24664_41064del16401), with frequencies of 15.47, 9.39, and 6.08%, respectively. These four mutations accounted for more than 87.0% of the total mutated alleles. Moreover, 19 different genotypes were identified. The types and distribution pattern of the mutations identified in this study, in comparison with other studies conducted in Iran, was most similar to the Kurdish population of Kermanshah Province, Iran. Due to the lack of information on α-thal in Lorestan Province, it was not possible to compare the mutation spectrum in the Lur and Lak populations. In conclusion, our results may help in setting up a strategy for an α-thal screening program and genetic counseling in the Lak people.

UI MeSH Term Description Entries
D007492 Iran A country bordering the Gulf of Oman, the Persian Gulf, and the Caspian Sea, between Iraq and Pakistan. The capital is Tehran. Islamic Republic of Iran
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006579 Heterozygote An individual having different alleles at one or more loci regarding a specific character. Carriers, Genetic,Genetic Carriers,Carrier, Genetic,Genetic Carrier,Heterozygotes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017085 alpha-Thalassemia A disorder characterized by reduced synthesis of the alpha chains of hemoglobin. The severity of this condition can vary from mild anemia to death, depending on the number of genes deleted. Hemoglobin H Disease,Thalassemia-alpha,A-Thalassemia,Alpha Thalassemia,Disease, Hemoglobin H,Thalassemia alpha,Thalassemia, Alpha,alpha-Thalassemias
D017422 Sequence Analysis, DNA A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis. DNA Sequence Analysis,Sequence Determination, DNA,Analysis, DNA Sequence,DNA Sequence Determination,DNA Sequence Determinations,DNA Sequencing,Determination, DNA Sequence,Determinations, DNA Sequence,Sequence Determinations, DNA,Analyses, DNA Sequence,DNA Sequence Analyses,Sequence Analyses, DNA,Sequencing, DNA
D055542 alpha-Globins Members of the alpha-globin family. In humans, they are encoded in a gene cluster on CHROMOSOME 16. They include zeta-globin and alpha-globin. There are also pseudogenes of zeta (theta-zeta) and alpha (theta-alpha) in the cluster. Adult HEMOGLOBIN is comprised of 2 alpha-globin chains and 2 beta-globin chains. alpha-Globin,alpha 1-globin,alpha-1 Globin,alpha-2 Globin,1-globin, alpha,Globin, alpha-1,Globin, alpha-2,alpha 1 Globin,alpha 2 Globin,alpha Globin,alpha Globins

Related Publications

Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
January 2015, Hemoglobin,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
January 2013, Hemoglobin,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
July 2007, Haematologica,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
November 2023, Hemoglobin,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
January 2008, Hemoglobin,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
January 2010, Hemoglobin,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
January 2013, Hemoglobin,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
November 2015, Clinical biochemistry,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
January 2010, Hemoglobin,
Keivan Moradi, and Mozaffar Aznab, and Susan Tahmasebi, and Zahra Dastafkan, and Leila Omidniakan, and Mahsa Ahmadi, and Reza Alibakhshi
March 2018, Hemoglobin,
Copied contents to your clipboard!